Noxopharm has been surging after announcing in early October that the US FDA has has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer.
CRO-67’s designation as an orphan drug supports the company’s development plan for the asset, and its future commercial value, as Noxopharm continues to build the data package that will be required for regulatory progression.
So far this year only two other Australian companies have received an ODD from the FDA, from a total of 260 issued.
Noxopharm followed that piece of good news with another announcement where it said that new data shows that SOF-VAC, its proprietary asset, significantly reduces mRNA-driven inflammation in animal testing.
In the animal study, inflammation was reduced by around 50% when comparing the inflammation induced by mRNA alone, versus mRNA plus SOF-VAC
Noxopharm (ASX:NOX)Noxopharm has been surging after announcing...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 11.0¢ | $4.623K | 42.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 154392 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 109573 | 3 |
View Market Depth
| Last trade - 15.45pm 08/08/2025 (20 minute delay) ? |
| NOX (ASX) Chart |